Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pyridostigmine

Pyridostigmine Reactions 1704, p328 - 2 Jun 2018 Diarrhoea: case report A 71-year-old man developed diarrhoea during treatment with pyridostigmine for acetylcholine receptor antibody- positive myasthenia gravis (MG) [duration of treatment to reaction onset and outcome not stated]. The man, who was diagnosed with acetylcholine receptor antibody-positive MG, started receiving oral pyridostigmine 120mg daily and tacrolimus. The symptoms of MG relieved. However, due to the subsequent disease progression, he was re-admitted and received treatment with methylprednisolone and immune globulin with an increased dose of tacrolimus. He developed diarrhoea secondary to pyridostigmine treatment. The man’s pyridostigmine treatment was discontinued. Further, he was diagnosed with small-cell lung cancer stage IVB and received chemoradiotherapy. He remained alive with no complaints and no disease progression to date. Author comment: "Pyridostigmine was stopped because the patient reported diarrhea as an adverse effect." Yamasaki M, et al. Acetylcholine receptor antibody-positive myasthenia gravis associated with small-cell lung cancer: A case report. Medicine 97: e0541, No. 17, Apr 2018. Available from: URL: http://doi.org/10.1097/MD.0000000000010541 - Japan 803322846 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Pyridostigmine

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Pyridostigmine

Abstract

Reactions 1704, p328 - 2 Jun 2018 Diarrhoea: case report A 71-year-old man developed diarrhoea during treatment with pyridostigmine for acetylcholine receptor antibody- positive myasthenia gravis (MG) [duration of treatment to reaction onset and outcome not stated]. The man, who was diagnosed with acetylcholine receptor antibody-positive MG, started receiving oral pyridostigmine 120mg daily and tacrolimus. The symptoms of MG relieved. However, due to the subsequent disease progression, he was...
Loading next page...
 
/lp/springer-journals/pyridostigmine-W0Hr0B2bIS
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46971-z
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p328 - 2 Jun 2018 Diarrhoea: case report A 71-year-old man developed diarrhoea during treatment with pyridostigmine for acetylcholine receptor antibody- positive myasthenia gravis (MG) [duration of treatment to reaction onset and outcome not stated]. The man, who was diagnosed with acetylcholine receptor antibody-positive MG, started receiving oral pyridostigmine 120mg daily and tacrolimus. The symptoms of MG relieved. However, due to the subsequent disease progression, he was re-admitted and received treatment with methylprednisolone and immune globulin with an increased dose of tacrolimus. He developed diarrhoea secondary to pyridostigmine treatment. The man’s pyridostigmine treatment was discontinued. Further, he was diagnosed with small-cell lung cancer stage IVB and received chemoradiotherapy. He remained alive with no complaints and no disease progression to date. Author comment: "Pyridostigmine was stopped because the patient reported diarrhea as an adverse effect." Yamasaki M, et al. Acetylcholine receptor antibody-positive myasthenia gravis associated with small-cell lung cancer: A case report. Medicine 97: e0541, No. 17, Apr 2018. Available from: URL: http://doi.org/10.1097/MD.0000000000010541 - Japan 803322846 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.